BLFS · Biolife Solutions Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $10.00M | - | - | - | - | - | - | - | - | - |
| Gross Profit | $17.50M | - | - | - | - | - | - | - | - | - |
| R&D | $2.65M | - | $2.71M | $2.72M | $2.20M | - | $2.05M | $2.38M | $3.53M | - |
| SG&A | $12.21M | - | $12.07M | $11.40M | $11.50M | - | $11.35M | $10.89M | $12.93M | - |
| Total Operating Expenses | $17.47M | - | $28.16M | $42.06M | $25.16M | - | $32.13M | $31.12M | $41.85M | - |
| D&A | $374.0K | - | $200.0K | $200.0K | $682.0K | - | $600.0K | $600.0K | $1.36M | - |
| Operating Income | $27.0K | - | ($89.0K) | ($16.64M) | ($1.22M) | - | ($1.56M) | ($2.79M) | ($10.13M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $62.0K | - | $82.0K | $126.0K | $14.0K | - | ($28.0K) | $0 | $131.0K | - |
| Net Income | $1.19M | - | $621.0K | ($15.84M) | ($448.0K) | - | ($1.70M) | ($20.72M) | ($10.22M) | - |
| EPS - Basic | $0.02 | - | $0.01 | ($0.33) | ($0.01) | - | ($0.04) | ($0.45) | ($0.22) | - |
| EPS - Diluted | $0.02 | - | $0.01 | ($0.33) | ($0.01) | - | ($0.04) | ($0.45) | ($0.22) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.82M | $33.04M | $29.48M | $31.90M | $66.94M | $95.39M | $23.98M | $22.01M | $29.69M | $35.41M |
| Accounts Receivable | $13.06M | $7.95M | $10.84M | $10.06M | $9.17M | $9.17M | $17.92M | $18.06M | $18.57M | $18.66M |
| Inventory | $32.83M | $30.16M | $27.82M | $27.69M | $27.57M | $29.01M | $32.18M | $32.50M | $43.41M | $43.46M |
| Accounts Payable | $3.75M | $1.49M | $2.89M | $3.21M | $3.30M | $3.57M | $3.84M | $4.21M | $4.98M | $6.94M |
| Current Assets | $133.22M | $136.56M | $126.57M | $125.43M | $131.13M | $148.76M | $89.38M | $88.20M | $111.70M | $120.60M |
| Total Assets | $400.91M | $405.88M | $392.08M | $387.24M | $395.14M | $399.49M | $381.65M | $374.98M | $401.60M | $412.71M |
| Current Liabilities | $18.25M | $22.98M | $27.15M | $28.31M | $27.72M | $32.73M | $32.17M | $30.82M | $38.66M | $42.18M |
| Long-term Debt | $2.50M | $0 | $0 | $0 | $2.50M | $5.00M | $7.82M | $10.45M | $15.68M | $18.31M |
| Total Liabilities | $28.68M | $34.00M | $38.34M | $40.09M | $42.52M | $50.58M | $56.19M | $53.53M | $68.20M | $75.05M |
| Stockholders' Equity | $372.23M | $371.89M | $353.74M | $347.15M | $352.62M | $348.91M | $325.46M | $321.44M | $333.40M | $337.66M |
| Retained Earnings | ($338.51M) | ($339.70M) | ($350.77M) | ($351.39M) | ($335.55M) | ($335.10M) | ($347.56M) | ($345.86M) | ($325.14M) | ($313.34M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($491.0K) | - | - | - | $1.73M | - | - | - | ($4.47M) | - |
| Investing Cash Flow | ($1.83M) | - | - | - | ($27.18M) | - | - | - | ($221.0K) | - |
| Financing Cash Flow | ($7.89M) | - | - | - | ($2.99M) | - | - | - | ($952.0K) | - |
| CapEx | $175.0K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($666.0K) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | -0.56 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | 5.0% | - | 11.7% | - | - | - | - | - | - | - |
| Return on assets | 0.3% | - | 0.2% | -4.1% | -0.1% | - | -0.4% | -5.5% | -2.5% | - |
| Return on equity | 0.3% | - | 0.2% | -4.6% | -0.1% | - | -0.5% | -6.4% | -3.1% | - |
| Return on invested capital | 0.0% | - | -0.0% | -3.8% | -0.3% | - | -0.4% | -0.7% | -2.3% | - |
| Liquidity | ||||||||||
| Current ratio | 7.30 | 5.94 | 4.66 | 4.43 | 4.73 | 4.54 | 2.78 | 2.86 | 2.89 | 2.86 |
| Quick ratio | 5.50 | 4.63 | 3.64 | 3.45 | 3.74 | 3.66 | 1.78 | 1.81 | 1.77 | 1.83 |
| Cash ratio | 1.25 | 1.44 | 1.09 | 1.13 | 2.41 | 2.91 | 0.75 | 0.71 | 0.77 | 0.84 |
| Leverage | ||||||||||
| Debt / Equity | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 | 0.05 | 0.05 |
| Debt / Assets | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 | 0.04 |
| Debt / EBITDA | 6.23 | - | 0.00 | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.08 | 1.09 | 1.11 | 1.12 | 1.12 | 1.14 | 1.17 | 1.17 | 1.20 | 1.22 |
| Liabilities / Assets | 0.07 | 0.08 | 0.10 | 0.10 | 0.11 | 0.13 | 0.15 | 0.14 | 0.17 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.30 | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 1198d | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 137d | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 954.0x | - | 2551.0x | - | - | - | - | - | - | - |
| P / B | 2.5x | - | 3.5x | 3.0x | 3.1x | - | 3.6x | 3.1x | 2.5x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | 2292.6x | - | 10932.0x | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 94.3% | -495.5% | 88.0% | - | 94.6% | 81.7% | 25.6% | - |
| Net income growth (YoY) | - | - | - | 23.6% | 95.6% | - | 94.2% | -103.1% | 25.5% | - |
| EPS growth (YoY) | - | - | - | 26.7% | 95.5% | - | 94.0% | -95.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 5.6% | 6.6% | 8.7% | 8.0% | 5.8% | 3.3% | -2.0% | -8.7% | -6.9% | -7.3% |
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing BIOLIFE SOLUTIONS INC against the 5 most active filers in the same SIC group.